YAP/TAZ pathway inhibitors

The Hippo signaling pathway is frequently dysregulated in human cancers, creating a critical dependency on YAP/TAZ activity. Clinical benefit of current therapies focused on downstream targets such as the TEAD transcription factors, is largely limited to specific Hippo-mutant tumor types such as mesothelioma. In collaboration with VIB we are developing potent, selective, and orally bioavailable small-molecule inhibitors targeting a broad range of YAP/TAZ-dependent solid tumors, including subsets of pancreatic, lung, head and neck, and bile duct cancer.